A Phase 2 interventional study of Roxadustat and Epoetin Alfa in End Stage Renal Disease and Anemia, sponsored by FibroGen. Completed at 25 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by FibroGen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing roxadustat in Kidney Failure, Chronic — 2 open to participants now, 3 under way, 1 of them phase 3. roxadustat · Kidney Failure, Chronic.
Among the 15 studies testing roxadustat in Kidney Failure, Chronic, this one is the 8th largest by enrollment, is the only one that started in 2010, is one of 5 in phase 2, and was the 1st registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →2 of the 15 studies testing roxadustat in Kidney Failure, Chronic are open now, in 1 country. Recruiting first, the newest first:
Mansoura University · Sites in Egypt
Ages 18+
Mansoura University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 7 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2010.
This study's enrollment of 161 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 161 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 5 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
Kyntra Bio has 9 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies testing roxadustat in Kidney Failure, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing roxadustat in Kidney Failure, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy and safety of roxadustat in participants with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) therapy, previously treated with intravenous (IV) epoetin alfa.
Dose ranging study with consecutive cohorts in two participant populations: participants normally responding to current anemia treatment (epoetin alfa) ("normoresponders": participants with baseline epoetin alfa dose at study entry 75 to 450 international units [IU]/kilograms [kg]/week) and participants not responding well to current treatment ("hyporesponders": participants with maintenance epoetin alfa dose above 450 IU/kg/week). Normoresponders are randomized to study drug roxadustat or epoetin alfa at a ratio of 3:1; hyporesponders are randomized to study drug roxadustat or epoetin alfa or placebo at a ratio of 2:1:1. The study objectives are to demonstrate that roxadustat is effective in maintaining hemoglobin (Hb) levels when converting from epoetin alfa and to establish optimum starting doses and dose adjustment regimens for Hb maintenance.
Key Inclusion Criteria:
Two most recent values obtained during screening period must be within the ranges set below:
i) Group A. Normoresponder Criteria: Hb range in the 8 weeks prior to randomization within 9.0 to 13.5 g/dL ii) Group B. Hyporesponder Criteria: Hb range in the 8 weeks prior to randomization within 8.5 to 13.5 g/dL
Epoetin alfa, dose requirements:
i) Group A. Normoresponder Criteria - Cohorts A-1 to A-12: Stable IV epoetin alfa dose at baseline (that is, no more than a 30% fluctuation in the weekly dose) during the 4 weeks prior to study Day -3
<!-- -->
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.0 milligrams (mg)/kg, administered orally 3 times weekly (TIW) in the morning of the day after dialysis (interdialytic days) for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 grams \[g\]/deciliter \[dL\]) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 85-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.3 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.3 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 100 mg, and 150 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 85-150 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (\>60 to 90 kg), and heavy weight (\>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Normoresponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort A. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
Drug: Epoetin Alfa
Hyporesponsive participants (with baseline epoetin alfa dosage 125-400 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Hyporesponsive participants (with baseline epoetin alfa dosage \>115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
Drug: Roxadustat
Hyporesponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort B. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
Drug: Epoetin Alfa
Hyporesponsive participants will receive placebo matched to roxadustat, administered orally TIW for 19 weeks.
Other: Placebo
Roxadustat will be administered per dose and schedule specified in the arms.
Also known as: FG-4592
Epoetin Alfa will be administered per dose and schedule specified in the arms.
Placebo matching to roxadustat will be administered per schedule specified in the arm.
Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. Last observation carried forward (LOCF) method was used to impute missing values.
Time frame: Week 7
Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.
Time frame: Week 7
Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks
The average of the mean Hb values that were above 11 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.
Time frame: Weeks 17, 18, 19, and 20
Number of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)
The average of the mean Hb values that were within 11-13 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.
Time frame: Weeks 17, 18, 19, and 20
Number of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)
The average of the mean Hb values that were within 10-13 g/dL at Weeks 17, 18, 19, and 20 are presented. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants. LOCF method was used to impute missing values.
Time frame: Weeks 17, 18, 19, and 20
Change From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.
Time frame: Baseline, Week 7
Change From Baseline in Hb at Weeks 8, 10, 12, 14, 17, 19, and 20 for Participants Treated for 7-19 Weeks
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.
Time frame: Baseline, Weeks 8, 10, 12, 14, 17, 19, and 20
Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 6 Weeks Only
Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
Time frame: Baseline up to Week 6
Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 19 Weeks
Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
Time frame: Baseline up to Week 19
Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks
Time frame: Week 7
Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks
Time frame: Week 7
Number of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
Time frame: Week 7
Number of Participants Treated for 7-19 Weeks Whose Hb Levels at Weeks 8, 10, 12, 14, 17, 19, and 20 Were Greater Than Their Baseline Level
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
Time frame: Weeks 8, 10, 12, 14, 17, 19, and 20
Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks
Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.
Time frame: Baseline up to Week 6
Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks
Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.
Time frame: Baseline up to Week 19
Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks
Time frame: Baseline up to Week 6
Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks
Time frame: Baseline up to Week 19
Rate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6
The rate of rise was computed as the slope of the regression line of change in Hb level (in g/dL) vs. time (in weeks) using Random Coefficient Model. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
Time frame: Baseline up to Week 6
Trough Plasma Concentration of Roxadustat and Epoetin Alfa
Time frame: Predose, 4, 8, 12, 24, 48, and 72 hours postdose at Weeks 1 and 6
| Milestone | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 2 | 10 | 36 | 4 | 5 | 4 | 4 |
| Received at least 1 dose of study drug | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 2 | 10 | 36 | 4 | 5 | 4 | 4 |
| Efficacy evaluable (ee) population | 9 | 10 | 9 | 11 | 11 | 11 | 11 | 10 | 2 | 10 | 31 | 1 | 3 | 4 | 3 |
| Completed | 10 | 10 | 11 | 10 | 7 | 9 | 9 | 9 | 2 | 8 | 33 | 2 | 1 | 3 | 0 |
| Not completed | 2 | 2 | 1 | 2 | 5 | 3 | 3 | 3 | 0 | 2 | 3 | 2 | 4 | 1 | 4 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 3 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Milestone | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 7 | 12 | 12 | 12 | 12 | 2 | 10 | 23 | 0 | 5 | 3 | 3 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 7 | 12 | 12 | 12 | 12 | 2 | 10 | 23 | 0 | 5 | 3 | 3 |
| Ee population for 19-week treatment | 0 | 0 | 0 | 6 | 11 | 11 | 11 | 10 | 2 | 10 | 22 | 0 | 3 | 3 | 2 |
| Completed | 0 | 0 | 0 | 5 | 7 | 9 | 9 | 9 | 2 | 8 | 21 | 0 | 1 | 2 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 5 | 3 | 3 | 3 | 0 | 2 | 2 | 0 | 4 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. Last observation carried forward (LOCF) method was used to impute missing values.
| Participants | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A (Epoetin Alfa) |
|---|---|---|---|---|---|
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only | 4 | 8 | 7 | 4 | 3 |
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.
| Participants | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|
| Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks | 0 | 1 | 2 | 0 |
The average of the mean Hb values that were above 11 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks | 4 | 4 | 6 | 5 | 6 | 2 | 4 | 8 | 0 | 0 | 0 |
The average of the mean Hb values that were within 11-13 g/dL at Weeks 17, 18, 19, and 20 are presented. LOCF method was used to impute missing values.
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks) | 4 | 1 | 6 | 5 | 6 | 2 | 3 | 8 | 0 | 0 | 0 |
The average of the mean Hb values that were within 10-13 g/dL at Weeks 17, 18, 19, and 20 are presented. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants. LOCF method was used to impute missing values.
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks) | 5 | 2 | 10 | 10 | 7 | 2 | 6 | 19 |
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.
| g/dL | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks | -0.40 ± 1.56 | 0.91 ± 1.59 | 0.71 ± 1.61 | 0.25 ± 1.86 | -0.15 ± 1.36 | -0.18 ± 1.55 | -0.32 ± 1.39 | -0.47 ± 0.94 | -0.00 ± 2.12 | 0.24 ± 1.82 | -0.51 ± 1.31 | -2.63 | -0.89 ± 0.74 | -0.28 ± 0.81 | -2.50 ± 0.23 |
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values.
| g/dL | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 8 | 0.49 ± 1.31 | 0.08 ± 1.56 | 0.01 ± 1.51 | -0.49 ± 1.49 | -0.29 ± 1.09 | 0.05 ± 2.05 | 0.20 ± 1.85 | -0.21 ± 1.02 | -0.89 ± 0.99 | -0.41 ± 1.52 | -2.37 ± 0.00 |
| Change at Week 10 | 0.56 ± 1.49 | 0.17 ± 1.65 | -0.17 ± 1.32 | -0.56 ± 1.35 | -0.27 ± 1.22 | -0.15 ± 0.07 | 0.26 ± 2.07 | -0.34 ± 1.19 | -1.46 ± 1.41 | 0.19 ± 1.48 | -2.37 ± 0.00 |
| Change at Week 12 | 0.26 ± 1.49 | 0.04 ± 1.57 | -0.10 ± 1.42 | -0.56 ± 1.44 | -0.35 ± 1.17 | -0.15 ± 0.92 | 0.38 ± 2.28 | -0.48 ± 1.20 | -2.02 ± 1.47 | -0.08 ± 2.50 | -2.37 ± 0.00 |
| Change at Week 14 | 0.53 ± 1.55 | -0.03 ± 1.73 | -0.27 ± 1.29 | -0.41 ± 1.44 | -0.24 ± 1.68 | -0.15 ± 1.77 | 0.33 ± 2.37 | -0.50 ± 1.23 | -2.29 ± 1.71 | 0.42 ± 1.83 | -2.37 ± 0.00 |
| Change at Week 17 | -0.09 ± 0.88 | -0.09 ± 1.96 | -0.27 ± 1.07 | -0.48 ± 1.42 | -0.27 ± 1.18 | -0.30 ± 0.85 | 0.02 ± 2.06 | -0.45 ± 1.57 | -2.69 ± 1.61 | 0.16 ± 2.27 | -2.37 ± 0.00 |
| Change at Week 19 | -0.11 ± 1.18 | -0.32 ± 1.84 | -0.28 ± 1.07 | -0.82 ± 1.19 | -0.35 ± 1.20 | 0.05 ± 0.07 | -0.10 ± 2.03 | -0.30 ± 1.43 | -3.02 ± 1.08 | 0.12 ± 2.27 | -2.37 ± 0.00 |
| Change at Week 20 | -0.39 ± 1.16 | -0.55 ± 1.88 | -0.55 ± 1.24 | -0.82 ± 1.27 | -0.33 ± 1.34 | 0.15 ± 0.07 | -0.57 ± 1.68 | -0.36 ± 1.50 | -2.82 ± 1.19 | 0.12 ± 2.14 | -2.47 ± 0.14 |
Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
| Participants | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A (Epoetin Alfa) |
|---|---|---|---|---|---|
| Dose Increased | 0 | 3 | 0 | 0 | 9 |
| Dose Reduced | 0 | 0 | 0 | 2 | 6 |
| Dose Interrupted | 4 | 7 | 4 | 0 | 3 |
| Dose Resume | 0 | 6 | 4 | 0 | 0 |
Number of participants who required dose increase, dose reduce, dose interruption or dose resume were reported. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) |
|---|---|---|---|---|---|---|---|---|
| Dose Increased | 2 | 5 | 5 | 4 | 7 | 1 | 8 | 12 |
| Dose Reduced | 3 | 3 | 5 | 4 | 4 | 1 | 6 | 11 |
| Dose Interrupted | 1 | 5 | 2 | 0 | 1 | 0 | 3 | 9 |
| Dose Resume | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 8 |
| Participants | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks | 3 | 3 | 5 | 5 | 4 | 3 | 6 | 6 | 0 | 1 | 19 | 0 | 2 | 3 | 0 |
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks | 3 | 4 | 3 | 6 | 6 | 0 | 1 | 13 | 2 | 3 | 0 |
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
| Participants | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A (Epoetin Alfa) |
|---|---|---|---|---|---|
| Number of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level | 3 | 7 | 6 | 3 | 2 |
Baseline was defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment, including Day 1 predose. LOCF method was used to impute missing values. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) |
|---|---|---|---|---|---|---|---|---|
| Week 8 | 3 | 6 | 4 | 4 | 4 | 1 | 6 | 9 |
| Week 10 | 3 | 6 | 4 | 4 | 5 | 0 | 6 | 7 |
| Week 12 | 3 | 6 | 6 | 4 | 3 | 1 | 5 | 9 |
| Week 14 | 3 | 6 | 6 | 4 | 1 | 1 | 6 | 6 |
| Week 17 | 2 | 5 | 5 | 4 | 4 | 1 | 6 | 6 |
| Week 19 | 2 | 4 | 5 | 2 | 4 | 1 | 6 | 8 |
| Week 20 | 3 | 3 | 5 | 2 | 5 | 2 | 5 | 7 |
Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.
| Participants | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks | 2 | 2 | 3 | 4 | 2 | 3 | 2 | 3 | 0 | 4 | 6 | 1 | 3 | 0 | 1 |
Rescue anemia treatment included any ESA dosing, RBC transfusion, or IV iron.
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks | 4 | 2 | 3 | 2 | 3 | 0 | 4 | 4 | 3 | 0 | 1 |
| Participants | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 4 | 6 | 0 | 0 | 1 | 0 |
| Participants | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks | 0 | 0 | 2 | 1 | 2 | 1 | 4 | 6 | 0 | 1 | 0 |
The rate of rise was computed as the slope of the regression line of change in Hb level (in g/dL) vs. time (in weeks) using Random Coefficient Model. Because of the small number of hyporesponders enrolled into this study, data for this secondary efficacy analysis as planned per protocol was not collected and summarized for hyporesponder participants.
| g/dL/week | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A (Epoetin Alfa) |
|---|---|---|---|---|---|
| Rate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6 | -0.0135 | 0.1926 | 0.1682 | -0.0220 | -0.1267 |
No measurements were reported for this outcome.
Collected over Baseline up to Week 23. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | — | 0/12 (0%) | 3/12 (25%) |
| Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | — | 3/12 (25%) | 1/12 (8.3%) |
| Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | — | 0/12 (0%) | 1/12 (8.3%) |
| Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | — | 4/12 (33.3%) | 4/12 (33.3%) |
| Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | — | 5/12 (41.7%) | 2/12 (16.7%) |
| Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | — | 3/12 (25%) | 2/12 (16.7%) |
| Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | — | 5/12 (41.7%) | 1/12 (8.3%) |
| Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | — | 3/12 (25%) | 2/12 (16.7%) |
| Cohort A-9 (Roxadustat 2.0 mg/kg) | — | 0/2 (0%) | 0/2 (0%) |
| Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | — | 3/10 (30%) | 3/10 (30%) |
| Cohorts A (Epoetin Alfa) | — | 6/36 (16.7%) | 2/36 (5.6%) |
| Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | — | 2/4 (50%) | 3/4 (75%) |
| Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | — | 2/5 (40%) | 2/5 (40%) |
| Cohort B (Epoetin Alfa) | — | 1/4 (25%) | 0/4 (0%) |
| Cohort B (Placebo) | — | 0/4 (0%) | 1/4 (25%) |
| Event | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| Diverticular perforationGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 0/4 | 0/5 | 1/4 | 0/4 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| Vascular pseudoaneurysm rupturedInjury, poisoning and procedural complications | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| Non-cardiac chest painGeneral disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| BacteraemiaInfections and infestations | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 0/4 | 1/5 | 0/4 | 0/4 |
| Cardiac failure congestiveCardiac disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/2 | 0/10 | 1/36 | 0/4 | 1/5 | 0/4 | 0/4 |
| Haemorrhagic strokeNervous system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 0/4 | 1/5 | 0/4 | 0/4 |
| Acute myocardial infarctionCardiac disorders | 0/12 | 2/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 0/4 | 0/5 | 0/4 | 0/4 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 1/10 | 0/36 | 0/4 | 0/5 | 0/4 | 0/4 |
| Event | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/12 | 0/12 | 1/12 | 1/12 | 0/12 | 0/12 | 0/12 | 2/12 | 0/2 | 1/10 | 0/36 | 0/4 | 1/5 | 0/4 | 0/4 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| HeadacheNervous system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| SyncopeNervous system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 0/12 | 0/12 | 2/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/2 | 2/10 | 0/36 | 1/4 | 0/5 | 0/4 | 1/4 |
| Catheter site painGeneral disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| Ingrowing nailSkin and subcutaneous tissue disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| Post procedural swellingInjury, poisoning and procedural complications | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| CellulitisInfections and infestations | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
| Otitis ExternaInfections and infestations | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/2 | 0/10 | 0/36 | 1/4 | 0/5 | 0/4 | 0/4 |
Safety population included all participants who were randomized and received at least 1 dose of study medication.
| Age, Continuous(years) | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 55.1 ± 12.1 | 58.8 ± 13.6 | 56.6 ± 10.8 | 50.8 ± 19.4 | 55.2 ± 10.6 | 58.7 ± 10.1 | 61.9 ± 11.9 | 55.7 ± 14.5 | 57.0 ± 17.0 | 55.8 ± 6.8 | 57.9 ± 11.0 | 55.0 ± 8.8 | 60.2 ± 5.9 | 47.0 ± 12.5 | 58.8 ± 8.6 | 56.3 ± 3.680644 |
| Sex: Female, Male(Participants) | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | Cohort A-9 (Roxadustat 2.0 mg/kg) | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | Cohorts A (Epoetin Alfa) | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | Cohort B (Epoetin Alfa) | Cohort B (Placebo) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 7 | 5 | 4 | 2 | 5 | 4 | 1 | 3 | 13 | 3 | 5 | 2 | 2 | 61 |
| Male | 8 | 11 | 5 | 7 | 8 | 10 | 7 | 8 | 1 | 7 | 23 | 1 | 0 | 2 | 2 | 100 |
Ran from May 2010 to primary completion in Oct 2012, 28 months.
Results were first posted in Jan 2022, 9 years 2 months after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 28 months is above that.
Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat